Cytokinetics Incorporated  (CYTK)
Other Ticker:  

Cytokinetics Incorporated's



CYTK Sales vs. its Competitors Q3 2023

Revenue Growth Comparisons

Net Income Comparison

<<  CYTK Stock Performance Comparisons

*Market share is calculated based on total revenue.

  News about Cytokinetics Incorporated Contracts

Cytokinetics Strengthens Leadership Team with Inducement Grants to CFO Sung H. Lee

Cytokinetics Grants Inducement Options and Units to CFO Sung H. LeeSOUTH SAN FRANCISCO, Calif., June 04, 2024 - Cytokinetics, Incorporated (Nasdaq: CYTK) has recently announced the granting of stock options, restricted stock units (RSUs), and performance stock units (PSUs) to Sung H. Lee, the company's newly appointed Executive Vice President and Chief Financial Officer. The grant of these equity awards serves as a material inducement to attract Mr. Lee to the company, whose employment began on May 8, 2024.Under the agreement, Mr. Lee will be eligible to purchase an aggregate of 53,417 shares of common stock through stock options. In addition to the stock options, 34,684 RSUs will be granted to Mr. Lee, whic...

Cytokinetics Demonstrates Statistically Significant and Clinically Meaningful Improvements in SEQUOIA-HCM Clinical Trial Results, Further Advancing Treatment for Hypertrophic Cardiomyopathy

Cytokinetics, a leading biopharmaceutical company, recently presented the primary results of the SEQUOIA-HCM clinical trial at the European Society of Cardiology Heart Failure 2024 Congress. The results, which were also published in the New England Journal of Medicine, highlighted significant improvements in the primary efficacy endpoint as well as all secondary endpoints. This groundbreaking research offers hope for patients with obstructive hypertrophic cardiomyopathy (HCM) and reinforces Cytokinetics' commitment to developing innovative treatments for cardiac conditions.Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy:Cytokinetics had previously announced three late-break...

Cytokinetics Set to Elevate Treatment for Hypertrophic Cardiomyopathy: Positive Insights from the SEQUOIA-HCM Study

Cytokinetics, a pre-eminent bio-pharmaceutical enterprise focusing on muscle biology and related diseases, has recently announced three late-breaking clinical trial presentations that shed light on the outcomes of the SEQUOIA-HCM study at the European Society of Cardiology (ESC) Heart Failure Congress 2024. These revelations follow their primary results release, showcasing encouraging topline results in patients with Obstructive Hypertrophic Cardiomyopathy (OHC).The study's crux is Cytokinetics' avant-garde drug, CK-274, which signifies a new therapeutic approach for patients with hypertrophic cardiomyopathy (HCM). HCM patients usually experience an overgrowth of heart muscles, leading to functional impairme...

Aficamten Treatment for 48 Weeks Shows Promising Results in Hypertrophic Cardiomyopathy Patients

Abstract:Hypertrophic cardiomyopathy (HCM) is a genetic heart condition characterized by abnormal thickening of the heart muscle, leading to impaired cardiac function and a range of clinical symptoms. Current treatment options for HCM focus on symptom management, and there is a critical need for novel therapies that target the underlying disease mechanism. Aficamten, a selective myosin inhibitor, has shown promise in early clinical trials for HCM. This article presents the findings from a 48-week open-label extension study, FOREST-HCM, which evaluated the long-term efficacy and safety of aficamten in HCM patients.HCM affects approximately 1 in 500 individuals worldwide, making it the most common inherited ca...

Who are Cytokinetics Incorporated's Competitors?


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com